Nurse Arzu Yildirim poses for the photographer as she holds a CoronaVac vaccine, made by Sinovac. (Photo | AP) 
World

Turkey to begin using China's Sinovac COVID vaccine as it reports 91 per cent efficacy in tests

Ankara in the next few days will also sign a deal with Pfizer/BioNTech for 4.5 million doses, with the option to buy 30 million more from the US pharmaceutical giant and its German partner.

From our online archive

ISTANBUL: Turkey will receive its first shipment of China's Sinovac coronavirus vaccine within days as preliminary domestic tests showed it was 91% effective, Health Minister Fahrettin Koca said on Thursday.

Ankara in the next few days will also sign a deal with Pfizer/BioNTech for 4.5 million doses, with the option to buy 30 million more from the US pharmaceutical giant and its German partner, Koca said.

Turkey will initially receive three million doses of Sinovac and have the option for 50 million more as it begins inoculations next month, starting with healthcare workers and the most vulnerable.

Koca said the first shipments of the Chinese vaccine will be sent to Turkey on Sunday.

The preliminary tests on 7,371 volunteers in Turkey showed that the Chinese vaccine was 91.25 per cent effective, although phase three tests were still not complete.

Turkey "will be able to vaccinate 1.5 million or even two million people per day," Koca said, adding that the "first stage" of vaccinations would cover nine million people.

The nation of 83 million has officially recorded 19,115 Covid-19 deaths and 2.2 million virus infections.

Supreme Court reserves order on Pawan Khera's anticipatory bail plea in defamation row

SC asks Centre to consider amending law on termination of pregnancy for rape survivors beyond 20 weeks

Delhi court grants bail to I-PAC director Vinesh Chandel in money laundering case after ED says 'no objection'

Kharge says no change in Karnataka CM 'for now' amid leadership tussle

Rajnath Singh says India halted Operation Sindoor on its own terms, was ready for long war

SCROLL FOR NEXT